Micron Products, Inc. a subsidiary of Arrhythmia Research Technology, Inc., has entered into a five-year, exclusive manufacturing agreement with New Era Orthopaedics LLC (NEO) for its total knee, hip and spine systems.
Micron to Manufacture for NEO
1 min read Premium comments
Secondary
Micron Products manufactures components, devices and equipment for medical, military, law enforcement and industrial applications. The company’s orthopedic implant machining operation produces quick-turn, high volume and patient-specific, finished orthopedic implants. Micron will be the sole producer of NEO’s FDA approved orthopedic implant designs. Micron expects to be fulfilling orders for NEO by the later half of 2015, according to its press release.
NEO, is a privately held medical device company headquartered in Hummelstown, Pennsylvania that “is responding to the need for appropriately priced, high quality primary joint replacement and spine implants in a market focused on economic value.” NEO claims “to provide state of the art design-optimized implants and instrumentation at a substantial discount via streamlined operations and a focus on the most commonly performed joint replacement and spine procedures.”
Salvatore Emma, Jr., president and chief executive officer of Micron, said, “We are pleased to be the exclusive manufacturer of NEO orthopedic implants as they introduce their cost effective designs to a rapidly expanding market. NEO has developed a strong reputation for innovative knee, hip and spine component and system designs. This agreement is a testament to our manufacturing capabilities, as well as our focus on high quality, rapid fulfillment processes. We expect significant interest from physicians worldwide for affordable, high quality components and systems to meet the growing demand in the orthopedic implant market.”
Craig Corrance, president and chief executive officer of NEO, said, “Our knee system is based on proven design principles for implants and instrumentation. We have been most impressed with Micron’s speed and agility, as well as their quality of service as a contract manufacturer. We look forward to a long and mutually beneficial relationship.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.